Jeff Yass’s Ascendis Pharma A/S ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.2M | Buy |
49,500
+10,700
| +28% | +$2.5M | ﹤0.01% | 2968 |
|
|
2026
Q1 | $8.87M | Sell |
38,800
-24,700
| -39% | -$5.54M | ﹤0.01% | 3295 |
|
|
2025
Q4 | $13.5M | Buy |
63,500
+1,900
| +3% | +$392K | ﹤0.01% | 2671 |
|
|
2025
Q3 | $12.2M | Buy |
61,600
+39,900
| +184% | +$7.44M | ﹤0.01% | 2780 |
|
|
2025
Q2 | $3.75M | Sell |
21,700
-48,100
| -69% | -$7.83M | ﹤0.01% | 4525 |
|
|
2025
Q1 | $10.9M | Buy |
69,800
+22,000
| +46% | +$3.14M | ﹤0.01% | 2423 |
|
|
2024
Q4 | $6.58M | Sell |
47,800
-104,400
| -69% | -$13.7M | ﹤0.01% | 3191 |
|
|
2024
Q3 | $22.7M | Buy |
152,200
+65,600
| +76% | +$8.86M | ﹤0.01% | 1704 |
|
|
2024
Q2 | $11.8M | Buy |
86,600
+26,600
| +44% | +$3.62M | ﹤0.01% | 2276 |
|
|
2024
Q1 | $9.07M | Buy |
60,000
+11,000
| +22% | +$1.57M | ﹤0.01% | 2737 |
|
|
2023
Q4 | $6.17M | Sell |
49,000
-8,000
| -14% | -$798K | ﹤0.01% | 3358 |
|
|
2023
Q3 | $5.34M | Sell |
57,000
-43,800
| -43% | -$4.1M | ﹤0.01% | 3404 |
|
|
2023
Q2 | $9M | Buy |
100,800
+70,000
| +227% | +$6.09M | ﹤0.01% | 2645 |
|
|
2023
Q1 | $3.3M | Sell |
30,800
-11,600
| -27% | -$1.33M | ﹤0.01% | 4137 |
|
|
2022
Q4 | $5.18M | Buy |
42,400
+31,200
| +279% | +$3.62M | ﹤0.01% | 3172 |
|
|
2022
Q3 | $1.16M | Sell |
11,200
-4,100
| -27% | -$389K | ﹤0.01% | 6262 |
|
|
2022
Q2 | $1.42M | Sell |
15,300
-69,500
| -82% | -$6.55M | ﹤0.01% | 5683 |
|
|
2022
Q1 | $9.95M | Buy |
84,800
+47,000
| +124% | +$5.44M | ﹤0.01% | 2564 |
|
|
2021
Q4 | $5.08M | Sell |
37,800
-10,700
| -22% | -$1.59M | ﹤0.01% | 3708 |
|
|
2021
Q3 | $7.73M | Sell |
48,500
-25,800
| -35% | -$3.53M | ﹤0.01% | 3256 |
|
|
2021
Q2 | $9.77M | Buy |
74,300
+27,400
| +58% | +$3.65M | ﹤0.01% | 2949 |
|
|
2021
Q1 | $6.04M | Buy |
46,900
+32,200
| +219% | +$4.89M | ﹤0.01% | 3554 |
|
|
2020
Q4 | $2.45M | Sell |
14,700
-23,500
| -62% | -$3.89M | ﹤0.01% | 4678 |
|
|
2020
Q3 | $5.89M | Sell |
38,200
-73,400
| -66% | -$10.6M | ﹤0.01% | 2841 |
|
|
2020
Q2 | $16.5M | Sell |
111,600
-14,300
| -11% | -$1.96M | ﹤0.01% | 1609 |
|
|
2020
Q1 | $14.2M | Sell |
125,900
-23,900
| -16% | -$3.11M | ﹤0.01% | 1434 |
|
|
2019
Q4 | $20.8M | Sell |
149,800
-26,700
| -15% | -$2.97M | 0.01% | 1377 |
|
|
2019
Q3 | $17M | Buy |
176,500
+37,500
| +27% | +$4.18M | 0.01% | 1464 |
|
|
2019
Q2 | $16M | Buy |
139,000
+37,000
| +36% | +$4.43M | 0.01% | 1461 |
|
|
2019
Q1 | $12M | Buy |
102,000
+47,700
| +88% | +$4.18M | ﹤0.01% | 1569 |
|
|
2018
Q4 | $3.4M | Sell |
54,300
-7,200
| -12% | -$452K | ﹤0.01% | 2755 |
|
|
2018
Q3 | $4.36M | Buy |
61,500
+4,800
| +8% | +$330K | ﹤0.01% | 2846 |
|
|
2018
Q2 | $3.77M | Buy |
+56,700
| New | +$3.73M | ﹤0.01% | 3076 |
|
Other funds holding ASND
RCM
ACA
JT
Jeff Yass's ASND Position: Q2 2026 in Review
Jeff Yass reduced its Ascendis Pharma A/S (ASND) stake by 96% in Q2 2026, selling an estimated $6.27M and leaving 1,215 shares worth $324K. The position accounts for ﹤0.01% of the portfolio, ranked #10874.
Jeff Yass first reported a position in ASND in Q2 2018 and has held it in 25 quarters since. The position peaked at $100M in Q4 2025. 310 funds tracked by Wall St. Rank hold ASND as of Q2 2026.
- Jeff Yass held 1,215 shares of Ascendis Pharma A/S worth $324K as of Q2 2026.
- Jeff Yass sold 26,847 Ascendis Pharma A/S shares in Q2 2026, an estimated $6.27M.
- Ascendis Pharma A/S made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10874 holding.
- Jeff Yass first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 25 quarters since.
- Jeff Yass's Ascendis Pharma A/S position peaked at $100M in Q4 2025.
- 310 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.